Sult1b1 Antibody

What is SULT1B1 and what is its biological function?

SULT1B1 (sulfotransferase family, cytosolic, 1B, member 1) is an enzyme that catalyzes the sulfation of various drugs and hormones. It plays a crucial role in phase II metabolism by transferring sulfo groups to xenobiotic and endogenous substrates, which generally increases their water solubility to facilitate excretion. SULT1B1 is expressed at highest levels throughout the human colon and small intestine but can also be found at moderate levels in human liver, kidney, and white blood cells .

The enzyme has significant pharmacological importance as certain SULT1B1 SNPs may influence the activity of thyroid hormones and affect the mutagenicity of polycyclic aromatic hydrocarbons . This suggests dual roles in both normal physiological processes and in modifying potential carcinogenic compounds. When designing experiments involving SULT1B1, researchers should consider this distribution pattern for selecting appropriate experimental models.

What are the essential characteristics of SULT1B1 protein for experimental detection?

Researchers working with SULT1B1 should be familiar with these key characteristics:

This information is essential for proper identification and validation of SULT1B1 in experimental settings . The consistency between calculated and observed molecular weights suggests minimal post-translational modifications affecting size, which is an important consideration when evaluating antibody specificity in Western blot applications.

What factors should researchers consider when selecting a SULT1B1 antibody?

When selecting a SULT1B1 antibody for research applications, consider:

• Antibody validation for specific applications: Verify the antibody has been validated for your intended use (WB, IHC, FC, etc.). For example, antibody 83228-1-RR has been validated for WB, IHC, FC (Intra), and ELISA applications .

• Species reactivity: Confirm the antibody recognizes SULT1B1 in your species of interest. The antibody described in the search results shows reactivity with human and mouse samples .

• Clonality and source: Consider whether a monoclonal or polyclonal antibody is more suitable. The antibody described is a recombinant rabbit IgG .

• Recognition of variants: For population studies, determine if the antibody can recognize known variants like the L145V polymorphism prevalent in populations of African descent .

• Target epitope: Understanding the immunogen used (e.g., SULT1B1 fusion protein Ag9009) can help predict epitope recognition and potential cross-reactivity .

How should researchers optimize Western blot protocols for SULT1B1 detection?

For optimal Western blot detection of SULT1B1:

• Sample selection: Use tissues with known high SULT1B1 expression like colon tissue as positive controls .

• Antibody dilution optimization: For antibody 83228-1-RR, the recommended dilution range is 1:5000-1:50000, but this should be empirically determined for each experimental system .

• Expected molecular weight verification: SULT1B1 should appear at approximately 35 kDa on Western blots .

• Loading controls: Include appropriate loading controls and a positive control sample (mouse colon tissue is recommended) .

• Membrane selection: PVDF membranes may provide better results for hydrophobic proteins like SULT1B1.

• Blocking optimization: Depending on background issues, adjust blocking conditions using either 5% non-fat dry milk or BSA in TBST.

• Signal detection method: For low abundance samples, consider using high-sensitivity chemiluminescence substrates or fluorescent secondary antibodies for quantitative analysis.

What protocol should researchers follow for immunohistochemical detection of SULT1B1?

For immunohistochemical detection of SULT1B1:

• Tissue preparation: Fixed, paraffin-embedded sections are suitable for SULT1B1 detection.

• Antigen retrieval: Use TE buffer pH 9.0 for optimal epitope exposure. Alternatively, citrate buffer pH 6.0 can be used if results are unsatisfactory .

• Antibody dilution: Use the SULT1B1 antibody at 1:200-1:800 dilution, optimizing for your specific tissue samples .

• Positive control selection: Mouse colon tissue is recommended as a positive control for SULT1B1 immunostaining .

• Visualization system: A polymer-based detection system with DAB chromogen is suitable for most applications.

• Counterstaining: Light hematoxylin counterstaining allows visualization of tissue architecture while maintaining SULT1B1 signal visibility.

• Negative controls: Include sections with primary antibody omitted and, if possible, tissue known to lack SULT1B1 expression.

What are the critical parameters for flow cytometric analysis of intracellular SULT1B1?

For successful flow cytometric detection of intracellular SULT1B1:

• Cell preparation: A431 cells have been validated for SULT1B1 detection by flow cytometry and can serve as a positive control .

• Fixation and permeabilization: Since SULT1B1 is intracellular, thorough permeabilization is essential. Test different permeabilization agents (saponin, Triton X-100, methanol) to determine optimal conditions.

• Antibody concentration: Use 0.25 μg of SULT1B1 antibody per 10^6 cells in a 100 μl suspension .

• Controls: Include isotype controls, fluorescence-minus-one (FMO) controls, and positive/negative cell controls.

• Multi-parameter considerations: When combining with other markers, consider fluorophore selection to minimize spectral overlap.

• Data analysis: Use appropriate gating strategies to exclude dead cells and debris before analyzing SULT1B1 expression.

• Quantification: Consider using calibration beads to convert fluorescence intensity to antibody binding capacity for more quantitative comparisons between samples.

How can researchers identify and characterize SULT1B1 variants in experimental samples?

To identify and characterize SULT1B1 variants:

• PCR amplification and sequencing:

  • Isolate RNA from tissue samples and synthesize cDNA

  • Amplify SULT1B1 using specific primers (e.g., sense: 5'-CTGAACAAAGGGATTAAATTGTGAGAACAACTGTC-3' and antisense: 5'-GAGATTGTCTGTAGTTGATTGAAACGAGGGCA-3')

  • Sequence the PCR product to identify potential variants

• Restriction enzyme analysis for L145V variant:

  • The L145V variant introduces a unique HpyCH4IV restriction site (A↓CGT)

  • Digest the PCR product with HpyCH4IV and analyze by gel electrophoresis

  • The L145V variant will be digested while the wild-type remains intact

• Functional characterization:

  • Clone both variant and wild-type forms

  • Express and purify the recombinant proteins

  • Compare enzyme kinetics between variants using standard substrates like p-nitrophenol and 1-naphthol

This approach allows researchers to both identify variants and assess their functional significance, providing insights into how genetic variation might affect drug metabolism or disease susceptibility.

What is the significance of the SULT1B1 L145V variant in research studies?

The SULT1B1 L145V variant (rs11569736) has significant research implications:

• Population distribution: This variant shows strong ethnic differences in frequency:

• Functional differences: The L145V variant shows altered enzyme kinetics:

  • Diminished Km values for small substrates like 1-naphthol and p-nitrophenol

  • Slower maximal rate of p-nitrophenol sulfation

  • These differences suggest altered substrate binding and catalytic properties

• Research implications:

  • Studies on drug metabolism should account for this variant in diverse populations

  • Clinical trial design may need stratification based on SULT1B1 genotype

  • The variant may contribute to population differences in drug responses or toxicity

The presence of this variant primarily in populations of African descent makes it particularly important to consider in pharmacogenetic studies and when developing personalized medicine approaches.

What methods are recommended for expressing and purifying recombinant SULT1B1 protein?

Based on published protocols, two effective strategies for SULT1B1 purification are:

• Ion Exchange Chromatography Approach:

  • Clone SULT1B1 into a bacterial expression vector (e.g., pKK233-2)

  • Transform into E. coli and induce with 2 mM IPTG

  • Lyse bacteria via sonication in buffer containing DTT and PMSF

  • Isolate cytosolic fraction by ultracentrifugation (100,000 x g)

  • Apply to DEAE-Sepharose column and elute with a NaCl gradient (10-300 mM)

  • SULT1B1 typically elutes at approximately 150 mM NaCl

• Affinity Chromatography (His-tagged) Approach:

  • Clone SULT1B1 into a vector with 6xHis tag (e.g., pPROEx-hta)

  • Transform into BL21-DE3-RIL E. coli for expression

  • Purify using metal affinity chromatography

  • This method yields higher purity protein suitable for binding studies

The choice between these methods depends on the intended application, with the His-tagged approach recommended for structural or binding studies requiring higher purity, while the ion exchange method may be sufficient for basic enzyme activity assays.

What are common issues encountered when using SULT1B1 antibodies and how can they be resolved?

Common challenges and solutions when working with SULT1B1 antibodies:

• Weak signal in Western blot:

  • Increase protein loading, particularly for tissues with lower expression

  • Optimize antibody concentration within the recommended range (1:5000-1:50000)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use enhanced chemiluminescence detection systems

• High background in immunohistochemistry:

  • Optimize blocking conditions (try different blocking agents)

  • Adjust antibody dilution within recommended range (1:200-1:800)

  • Test different antigen retrieval methods (compare TE buffer pH 9.0 vs. citrate buffer pH 6.0)

  • Increase washing steps duration and frequency

• Non-specific bands in Western blot:

  • Use gradient gels for better protein separation

  • Verify molecular weight (SULT1B1 should appear at 35 kDa)

  • Compare with recombinant SULT1B1 protein as a positive control

  • Consider genetic variants that might produce slightly different patterns

• Variable results across samples:

  • Consider SULT1B1 variants (e.g., L145V) that might affect protein levels or antibody binding

  • Standardize sample collection and processing protocols

  • Include internal controls in each experiment for normalization

How should SULT1B1 antibody storage and handling be optimized for research use?

For optimal SULT1B1 antibody performance:

• Storage conditions:

  • Store at -20°C where it remains stable for one year after shipment

  • The antibody described is supplied in PBS with 0.02% sodium azide and 50% glycerol (pH 7.3), which helps maintain stability

  • Some preparations (20μl sizes) contain 0.1% BSA for additional stability

• Handling best practices:

  • Avoid repeated freeze-thaw cycles

  • Briefly centrifuge the vial before opening to collect liquid

  • Use clean, RNase/DNase-free pipette tips

  • Return to -20°C promptly after use

• Working solution preparation:

  • Prepare fresh dilutions for each experiment

  • Dilute in buffers with carrier proteins (0.1-0.5% BSA) to prevent non-specific adsorption

  • For IHC applications, antibody diluent with background-reducing components may improve results

• Quality control measures:

  • Periodically validate antibody performance with positive controls

  • Document lot numbers and observe for any lot-to-lot variation

  • Consider aliquoting for long-term studies to ensure consistency

What controls are essential when validating SULT1B1 antibody specificity?

A comprehensive validation approach for SULT1B1 antibodies should include:

• Positive tissue controls:

  • Mouse colon tissue for both Western blot and IHC applications

  • A431 cells for flow cytometry

  • These provide known sources of SULT1B1 expression to validate detection

• Negative controls:

  • Primary antibody omission control

  • Isotype-matched irrelevant antibody control

  • Tissues known to lack SULT1B1 expression

  • These help identify non-specific binding

• Molecular validation:

  • Recombinant SULT1B1 protein as a positive control

  • siRNA/shRNA knockdown of SULT1B1 to demonstrate specificity

  • Peptide competition assay by pre-incubating antibody with immunizing peptide

• Cross-validation methods:

  • Compare results with alternative antibodies targeting different SULT1B1 epitopes

  • Correlate antibody signal with mRNA expression data

  • For known variants like L145V, include samples with different genotypes to assess any detection differences

These validation approaches should be documented to ensure confidence in experimental results, particularly for studies examining SULT1B1 in diverse populations where variants may affect detection.

How should researchers account for SULT1B1 genetic variants in experimental design?

When designing studies involving SULT1B1 across diverse populations:

• Genotyping considerations:

  • Screen for the L145V variant (rs11569736) especially in populations of African descent where frequencies range from 5.6-11.5%

  • Consider using restriction enzyme analysis with HpyCH4IV for rapid screening

  • Include subjects with known genotypes to assess functional differences

• Stratified analysis approach:

  • Analyze data separately by genotype before pooling

  • Compare enzyme activity between genotype groups

  • Assess if pharmacological responses correlate with genotype

• Antibody selection considerations:

  • Verify that selected antibodies recognize both wild-type and variant SULT1B1

  • Determine if epitope recognition is affected by the L145V substitution

  • Use recombinant proteins of both variants as controls

• Functional characterization:

  • Measure enzyme kinetics for both variants with relevant substrates

  • The L145V variant shows altered kinetic properties including diminished Km values for small substrates and slower maximal rate of p-nitrophenol sulfation

  • These differences may affect drug metabolism and toxicity profiles

• Reporting standards:

  • Document SULT1B1 genotypes of study participants

  • Report allele frequencies in the studied population

  • Explicitly state which SULT1B1 variant(s) were used in experimental work

What enzymatic assays best characterize functional differences between SULT1B1 variants?

To characterize functional differences between SULT1B1 variants:

• Substrate panel selection:

  • Small substrates: p-nitrophenol and 1-naphthol have shown different kinetic parameters between variants

  • Large substrates: 1-hydroxypyrene can reveal differences in active site accommodation of larger molecules

  • Physiologically relevant substrates: thyroid hormones and steroid hormones may show clinically significant differences

• Kinetic parameter determination:

  • Measure initial velocities at varying substrate concentrations

  • Calculate and compare Km, Vmax, and kcat/Km values between variants

  • The L145V variant shows diminished Km values for small substrates compared to wild-type

• Inhibition studies:

  • Test susceptibility to known SULT inhibitors

  • Determine if variants show differential inhibition patterns

  • This may reveal differences in active site structure or substrate binding

• pH and temperature dependency:

  • Determine optimal pH and temperature ranges for each variant

  • Assess thermal stability differences

  • Changes in these parameters may reflect structural differences affecting catalytic activity

• In vitro to in vivo correlation:

  • Correlate in vitro enzymatic differences with clinical phenotypes

  • Design cell-based assays mimicking physiological conditions

  • Consider factors like substrate availability and competing enzymes

What emerging technologies could advance SULT1B1 research?

Cutting-edge approaches for SULT1B1 research include:

• CRISPR-Cas9 genome editing:

  • Generate isogenic cell lines differing only in SULT1B1 genotype (wild-type vs. L145V)

  • Create knock-in animal models with human SULT1B1 variants

  • These tools allow direct comparison of variant effects in identical genetic backgrounds

• Cryo-EM and protein structural analysis:

  • Determine high-resolution structures of wild-type and variant SULT1B1

  • Map differences in substrate binding pockets

  • Identify structural changes explaining altered kinetic properties of the L145V variant

• Single-cell analysis:

  • Examine SULT1B1 expression heterogeneity within tissues

  • Correlate with metabolic phenotypes at cellular level

  • Particularly relevant for tissues with high expression like colon and small intestine

• Pharmacogenomic screening platforms:

  • Develop high-throughput assays to test drug metabolism by different SULT1B1 variants

  • Screen compound libraries for variant-specific inhibitors or substrates

  • These approaches could identify drugs requiring genotype-specific dosing

• Computational modeling:

  • Molecular dynamics simulations of wild-type and variant SULT1B1

  • Predict effects of the L145V substitution on substrate binding and catalysis

  • Virtual screening for novel substrates or inhibitors

How might SULT1B1 research inform precision medicine approaches?

SULT1B1 research has significant implications for precision medicine:

• Pharmacogenetic biomarker development:

  • The L145V variant could serve as a biomarker for drug response prediction in populations of African descent

  • Research should identify specific drugs metabolized differently by SULT1B1 variants

  • Develop clinical assays for SULT1B1 genotyping to guide treatment decisions

• Population-specific dosing guidelines:

  • Establish if standard drug dosing should be adjusted based on SULT1B1 genotype

  • Particularly relevant for populations with higher L145V frequency (African ancestry)

  • Create pharmacogenetic algorithms incorporating SULT1B1 status alongside other variants

• Risk assessment for environmental exposures:

  • Determine if SULT1B1 variants affect detoxification of environmental carcinogens

  • The variant may influence the mutagenicity of polycyclic aromatic hydrocarbons

  • This could inform personalized prevention strategies for certain cancers

• Clinical trial design considerations:

  • Incorporate SULT1B1 genotyping in clinical trials of drugs potentially metabolized by this enzyme

  • Stratify analysis by genotype to identify variant-specific responses

  • This approach may reveal previously undetected efficacy or safety signals